Clinical Trial

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of KH607 in 120 participants diagnosed with moderate or severe Major Depressive Disorder.
Protocol Amendment History 3 changes
critical Completed without a posted recruiting period 2026-07-29
notable Primary completion pushed: 2025-12 -> 2026-02-09 2026-07-29
minor Completion moved earlier: 2026-04 -> 2026-02-09 2026-07-29
Trial Details
NCT Number NCT07101120
Lead Sponsor Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Conditions Major Depressive Disorder (MDD)
Enrollment 126 participants
Start Date 2025-03-19
Primary Completion 2026-02-09 (estimated)
Study Completion 2026-02-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-28